3 Reasons to Buy This Dividend King After Its Steep Sell-Off

Core Viewpoint - Abbott Laboratories experienced a significant drop in share price following its Q4 2025 earnings report, which revealed lower-than-expected revenue, leading to concerns among investors about the company's performance and future growth prospects [1]. Group 1: Financial Performance - Abbott reported Q4 revenue of $11.5 billion, missing Wall Street's expectation of $11.8 billion, primarily due to challenges in its nutrition segment [3]. - Despite the revenue miss, Abbott's adjusted diluted earnings per share (EPS) increased by 12% year over year, aligning with analysts' estimates [3]. - The company anticipates overall revenue growth to accelerate in 2026, projecting organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80, indicating a 10% year-over-year growth at the midpoint [4]. Group 2: Market Position and Future Outlook - Abbott is recognized as a Dividend King, having increased its dividend for 54 consecutive years, making it an attractive option for income investors [2]. - The company is expected to implement changes in its nutrition business to drive a return to growth in the second half of 2026 [3]. - Abbott's diversified business model and comprehensive product portfolio position it favorably within the medtech and diagnostics markets, as stated by CEO Robert Ford [6].